Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

50.05 +0.19 (+0.37%)
Streaming Delayed Price Updated: 11:37 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
89 90 Next >
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments. 
Via Benzinga
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now... 
Via Benzinga
Topics Bankruptcy
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant? 
Via MarketBeat
Topics Earnings
Novo Nordisk's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook
The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales? 
Via Investor's Business Daily
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
Hims & Hers Names New COO. Stock Rallies.
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas. 
Via Benzinga
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution. 
Via Benzinga
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential. 
Via Benzinga
Why Is Novo Nordisk Stock Trading Higher On Friday?
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity. 
Via Benzinga
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024. 
Via MarketBeat
Topics Regulatory Compliance
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives. 
Via Benzinga
CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance
CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance. 
Via Benzinga
Why Novo Nordisk Stock Popped Today
Guess WHO thinks Novo Nordisk stock is a buy now? 
Via The Motley Fool
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Affordable Growth Candidate
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Affordable Growth Candidate 
Via Chartmill
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Why Novo Nordisk Stock Is Soaring Today
Via The Motley Fool
Topics Stocks World Trade
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators
Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers. 
Via Stocktwits
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
The companies will collaborate to improve access to weight-loss drugs in the U.S. 
Via Investor's Business Daily
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novo Nordisk’s Weight-Loss Drug Wegovy Launched In Thailand, Marks Entry Into Southeast Asia
Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023. 
Via Stocktwits
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its... 
Via Stocktwits
Topics Intellectual Property
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.